RIGEL PHARMACEUTICALS INC (RIGL) Fundamental Analysis & Valuation

NASDAQ:RIGL • US7665597024

28.34 USD
-1.18 (-4%)
Last: Mar 6, 2026, 12:17 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This RIGL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to RIGL. RIGL was compared to 520 industry peers in the Biotechnology industry. RIGL is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. RIGL has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! This makes RIGL very considerable for value and growth investing!


Dividend Valuation Growth Profitability Health

6

1. RIGL Profitability Analysis

1.1 Basic Checks

  • In the past year RIGL was profitable.
  • RIGL had a positive operating cash flow in the past year.
  • In the past 5 years RIGL reported 4 times negative net income.
  • In multiple years RIGL reported negative operating cash flow during the last 5 years.
RIGL Yearly Net Income VS EBIT VS OCF VS FCFRIGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 46.72%, RIGL belongs to the top of the industry, outperforming 99.23% of the companies in the same industry.
  • The Return On Equity of RIGL (96.34%) is better than 99.42% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 63.44%, RIGL belongs to the top of the industry, outperforming 99.62% of the companies in the same industry.
Industry RankSector Rank
ROA 46.72%
ROE 96.34%
ROIC 63.44%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RIGL Yearly ROA, ROE, ROICRIGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

  • The Profit Margin of RIGL (40.17%) is better than 97.50% of its industry peers.
  • The Operating Margin of RIGL (42.17%) is better than 99.04% of its industry peers.
  • RIGL has a better Gross Margin (93.10%) than 93.65% of its industry peers.
  • In the last couple of years the Gross Margin of RIGL has declined.
Industry RankSector Rank
OM 42.17%
PM (TTM) 40.17%
GM 93.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
RIGL Yearly Profit, Operating, Gross MarginsRIGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. RIGL Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), RIGL is creating value.
  • Compared to 1 year ago, RIGL has more shares outstanding
  • RIGL has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for RIGL has been reduced compared to a year ago.
RIGL Yearly Shares OutstandingRIGL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
RIGL Yearly Total Debt VS Total AssetsRIGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -1.50, we must say that RIGL is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of RIGL (-1.50) is comparable to the rest of the industry.
  • The Debt to FCF ratio of RIGL is 0.88, which is an excellent value as it means it would take RIGL, only 0.88 years of fcf income to pay off all of its debts.
  • RIGL's Debt to FCF ratio of 0.88 is amongst the best of the industry. RIGL outperforms 94.42% of its industry peers.
  • RIGL has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of RIGL (0.25) is worse than 65.96% of its industry peers.
  • Even though the debt/equity ratio score it not favorable for RIGL, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 0.88
Altman-Z -1.5
ROIC/WACC7.22
WACC8.79%
RIGL Yearly LT Debt VS Equity VS FCFRIGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 2.28 indicates that RIGL has no problem at all paying its short term obligations.
  • With a Current ratio value of 2.28, RIGL is not doing good in the industry: 73.65% of the companies in the same industry are doing better.
  • A Quick Ratio of 2.14 indicates that RIGL has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.14, RIGL is doing worse than 73.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.28
Quick Ratio 2.14
RIGL Yearly Current Assets VS Current LiabilitesRIGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. RIGL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 4307.14% over the past year.
  • Looking at the last year, RIGL shows a very strong growth in Revenue. The Revenue has grown by 79.13%.
  • Measured over the past years, RIGL shows a very strong growth in Revenue. The Revenue has been growing by 24.77% on average per year.
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%

3.2 Future

  • RIGL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 38.70% yearly.
  • The Revenue is expected to grow by 15.91% on average over the next years. This is quite good.
EPS Next Y619.43%
EPS Next 2Y109.9%
EPS Next 3Y73.71%
EPS Next 5Y38.7%
Revenue Next Year69.07%
Revenue Next 2Y27.77%
Revenue Next 3Y22.37%
Revenue Next 5Y15.91%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RIGL Yearly Revenue VS EstimatesRIGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
RIGL Yearly EPS VS EstimatesRIGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

10

4. RIGL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 4.59, which indicates a rather cheap valuation of RIGL.
  • Based on the Price/Earnings ratio, RIGL is valued cheaper than 99.04% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.69, RIGL is valued rather cheaply.
  • The Price/Forward Earnings ratio is 6.84, which indicates a rather cheap valuation of RIGL.
  • RIGL's Price/Forward Earnings ratio is rather cheap when compared to the industry. RIGL is cheaper than 98.27% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 24.79. RIGL is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 4.59
Fwd PE 6.84
RIGL Price Earnings VS Forward Price EarningsRIGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 99.23% of the companies in the same industry are more expensive than RIGL, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, RIGL is valued cheaper than 98.65% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7.55
EV/EBITDA 3.05
RIGL Per share dataRIGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • RIGL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of RIGL may justify a higher PE ratio.
  • A more expensive valuation may be justified as RIGL's earnings are expected to grow with 73.71% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y109.9%
EPS Next 3Y73.71%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RIGL Dividend Analysis

5.1 Amount

  • RIGL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RIGL Fundamentals: All Metrics, Ratios and Statistics

RIGEL PHARMACEUTICALS INC

NASDAQ:RIGL (3/6/2026, 12:17:42 PM)

28.34

-1.18 (-4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-02
Earnings (Next)05-04
Inst Owners85.11%
Inst Owner Change6.52%
Ins Owners2.59%
Ins Owner Change6.76%
Market Cap514.37M
Revenue(TTM)282.08M
Net Income(TTM)113.30M
Analysts80
Price Target47.94 (69.16%)
Short Float %21.57%
Short Ratio9.16
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.05%
Min EPS beat(2)24.64%
Max EPS beat(2)67.46%
EPS beat(4)4
Avg EPS beat(4)188.12%
Min EPS beat(4)24.64%
Max EPS beat(4)592.43%
EPS beat(8)7
Avg EPS beat(8)242.36%
EPS beat(12)11
Avg EPS beat(12)181.29%
EPS beat(16)14
Avg EPS beat(16)138.58%
Revenue beat(2)2
Avg Revenue beat(2)11.07%
Min Revenue beat(2)10.05%
Max Revenue beat(2)12.08%
Revenue beat(4)4
Avg Revenue beat(4)12.62%
Min Revenue beat(4)9.15%
Max Revenue beat(4)19.17%
Revenue beat(8)7
Avg Revenue beat(8)10.41%
Revenue beat(12)11
Avg Revenue beat(12)14.43%
Revenue beat(16)12
Avg Revenue beat(16)11.18%
PT rev (1m)0.71%
PT rev (3m)9.73%
EPS NQ rev (1m)7.09%
EPS NQ rev (3m)17.09%
EPS NY rev (1m)-0.53%
EPS NY rev (3m)19.02%
Revenue NQ rev (1m)1.14%
Revenue NQ rev (3m)3.4%
Revenue NY rev (1m)0.27%
Revenue NY rev (3m)4.3%
Valuation
Industry RankSector Rank
PE 4.59
Fwd PE 6.84
P/S 1.82
P/FCF 7.55
P/OCF 7.54
P/B 4.37
P/tB 5.57
EV/EBITDA 3.05
EPS(TTM)6.17
EY21.77%
EPS(NY)4.14
Fwd EY14.61%
FCF(TTM)3.75
FCFY13.25%
OCF(TTM)3.76
OCFY13.25%
SpS15.54
BVpS6.48
TBVpS5.08
PEG (NY)0.01
PEG (5Y)N/A
Graham Number29.99
Profitability
Industry RankSector Rank
ROA 46.72%
ROE 96.34%
ROCE 80.3%
ROIC 63.44%
ROICexc 854.98%
ROICexgc N/A
OM 42.17%
PM (TTM) 40.17%
GM 93.1%
FCFM 24.16%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score7
Asset Turnover1.16
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 0.88
Debt/EBITDA 0.25
Cap/Depr 1.57%
Cap/Sales 0.01%
Interest Coverage 17.61
Cash Conversion 56.17%
Profit Quality 60.14%
Current Ratio 2.28
Quick Ratio 2.14
Altman-Z -1.5
F-Score7
WACC8.79%
ROIC/WACC7.22
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
EPS Next Y619.43%
EPS Next 2Y109.9%
EPS Next 3Y73.71%
EPS Next 5Y38.7%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
Revenue Next Year69.07%
Revenue Next 2Y27.77%
Revenue Next 3Y22.37%
Revenue Next 5Y15.91%
EBIT growth 1Y1151.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year546.96%
EBIT Next 3Y91.91%
EBIT Next 5Y95.89%
FCF growth 1Y286.79%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y418.44%
OCF growth 3Y74.92%
OCF growth 5YN/A

RIGEL PHARMACEUTICALS INC / RIGL FAQ

What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?

ChartMill assigns a fundamental rating of 7 / 10 to RIGL.


What is the valuation status for RIGL stock?

ChartMill assigns a valuation rating of 10 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.


Can you provide the profitability details for RIGEL PHARMACEUTICALS INC?

RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.


How financially healthy is RIGEL PHARMACEUTICALS INC?

The financial health rating of RIGEL PHARMACEUTICALS INC (RIGL) is 7 / 10.